KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate

Key Takeaways KYMR started dosing in the phase IIb BREADTH study of KT-621 for eosinophilic asthma.KYMR's asthma study tests three doses of KT-621 in adults over 12 weeks, with FEV1 as the primary endpoint.KYMR is also running another phase IIb AD study of KT-621, with asthma data due in late 2027.Kymera Therapeutics (KYMR) announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to-severe eosinophilic asthma. KT-621 is an investigational, first-in-class, once-daily, ...